Canada: IP Monitor - A Healthy Development? A Review Of CIPO’s New "Medical Method" Examination Guidelines

On March 18, 2015 the Canadian Intellectual Property Office ("CIPO") issued a Patent Notice: Revised Examination Practice Respecting Medical Uses (the "Notice"), ostensibly to reflect the Federal Court decision in AbbVie Biotechnology Ltd v Canada (AG), 2014 FC 1251 ("AbbVie"). Practice notices do not have the force of law but are generally closely adhered to by Canadian patent examiners in reviewing patent applications.

The patentability of methods of medical treatment in Canada

Generally speaking, Canadian case law holds that medical methods are not patentable although new medical uses (of new or known products) may be patentable. A claim will be considered a method of medical treatment and be unpatentable subject matter if it interferes with a physician's skill and judgment.

AbbVie Biotechnology Ltd v Canada (AG)

AbbVie appealed a decision of the Commissioner of Patents refusing its patent on the basis of the claims being directed to methods of medical treatment. The patent application pertained to a fixed dosing regimen for AbbVie's drug HUMIRA®. The Court considered a subset of the claims advanced before the Patent Appeal Board, which included syringe, Swiss-type use and use claims. The construction of the claims was not in dispute, and Justice Kane of the Federal Court characterized the essential elements of the claims as being a preloaded syringe of 40 mg of the drug HUMIRA® for the treatment of arthritic disease or an inflammatory bowel disease; administered subcutaneously; for use on an every other week dosing interval of 14 days (i.e., bi-weekly). The claims therefore included a fixed dose and dosing interval.

The Court reviewed the Commissioner's decision under a standard of correctness. The Commissioner argued that prior case law,1 which it believed was reflected in CIPO's earlier practice notice PN 2013-04, prohibited patenting of "how and when" a drug is administered. The Commissioner further argued that although the claims at issue recited a fixed dose and fixed schedule, the physician's skill and judgment was still required to adhere to that dosing regimen at the outset.

Justice Kane rejected the Commissioner's broad interpretation, noting that under the Commissioner's approach, claims which had been found permissible in other cases should have been impermissible for including a dosage and dosing interval:

The respondent's [Commissioner's] approach appears to overlook that the professional- in this case the physician- must still exercise their skill and judgment to decide whether or not the claimed invention should be used as claimed (i.e., whether it is appropriate for a particular patient). Once that is determined, there may be no further need to exercise skill and judgment to vary the claimed way to use the invention. It is not expected and it is not necessary. The expert evidence about the invention will inform whether skill and judgment is expected or necessary to be exercised. [emphasis added]

Justice Kane held that the claims at issue pertained to a fixed dose and a fixed interval, which obviated a physician's skill and judgment in prescribing a dosing regimen. Thus, Justice Kane held that AbbVie's patent claims were not methods of medical treatment and directed the Commissioner of Patents to allow the patent application to issue.

Revised examination practice respecting medical uses

The Notice released in response to AbbVie supersedes the previous examination guidelines published by CIPO in June 2013. The previous guidelines focussed on an analysis of claim language and an identification of whether the essential elements of the claim reflected "how" to treat a patient (not allowable) versus one directed to "what" is used to treat a patient (allowable).

Under the new Notice, CIPO endorses an approach that considers the specification as a whole in answering this "how" or "what" question:

To perform a purposive construction, an examiner identifies the problem the inventors set out to address and the solution disclosed. This exercise generally must be performed considering the specification as a whole, recognizing that the description guides the identification of the problem and solution.

This is problematic for prosecution internationally because for most jurisdictions broad support for various embodiments (e.g. ranges and alternatives) is desirable. The Notice acknowledges that "an applicant is entitled to claim less that the entire invention if so desired", but asserts that "a proper identification of the actual invention, grounded in a purposive construction of the claims, is nevertheless necessary in order to assess whether the claim is patentable."

If the examiner determines that the essential elements are directed to "how" to treat a patient then the examiner is to determine "whether the essential element prevents, interferes with or requires the professional skill of a physician". It is not clear whether CIPO will permit evidence to be adduced on this point or whether the analysis will continue to rely on the interpretation of the specification. In a positive development, the Notice does acknowledge that "essential elements that narrow treatment to a fixed dosage, a fixed dosage regimen, a patient subpopulation or to a particular administration site are not considered to point to a limitation of a physician's professional skill or judgment."

This approach of characterizing the claims based on a problem-solution review of the specification is not the approach taken in AbbVie (the analysis having been based on an agreed construction.) Time will tell if AbbVie and the Notice open the door more broadly for patenting dosage form and regimen claims in Canada. It may be that in turning to the specification, CIPO is looking for a substitute to the expert evidence relied upon in the case law to determine whether the invention in fact restricts the skill and judgment of a physician. It is also possible that the Notice will maintain the status quo of severely restricting protection for dosage forms and regimens despite a decision holding that the standard espoused by CIPO to-date has been unduly restrictive.


1. Janssen Inc v Mylan Pharmaceuticals ULC, 2010 FC 1123.

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions